Quadrant Capital Group LLC Pacira Bio Sciences, Inc. Transaction History
Quadrant Capital Group LLC
- $1.42 Billion
- Q3 2024
A detailed history of Quadrant Capital Group LLC transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Quadrant Capital Group LLC holds 469 shares of PCRX stock, worth $9,131. This represents 0.0% of its overall portfolio holdings.
Number of Shares
469
Previous 487
3.7%
Holding current value
$9,131
Previous $13,000
46.15%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding PCRX
# of Institutions
263Shares Held
50.4MCall Options Held
429KPut Options Held
391K-
Black Rock Inc. New York, NY8.01MShares$156 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.3MShares$103 Million0.0% of portfolio
-
Pacer Advisors, Inc. Malvern, PA4.96MShares$96.6 Million0.18% of portfolio
-
State Street Corp Boston, MA2.01MShares$39.2 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.98MShares$38.5 Million0.05% of portfolio
About Pacira BioSciences, Inc.
- Ticker PCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 45,824,200
- Market Cap $892M
- Description
- Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...